Nanox.AI

The software subsidiary is purely algorithmic, mining existing CT scans with no scanner or services layer of its own. The complication is corporate rather than technical: since the 2021 acquisition this is the AI arm of a medical imaging HARDWARE company whose primary business is a multi-source digital X-ray system, and the parent's strategy pairs that hardware with a teleradiology network and pay-per-scan model. The algorithms are genuinely central to this business unit; they are one line of a hardware company. Graded B rather than A to reflect that structural position.

Cleared as clinical decision assist, presenting findings for radiologist evaluation rather than issuing conclusions. The opportunistic screening model creates a distinctive oversight question worth naming: the algorithm surfaces findings on scans ordered for entirely unrelated reasons, which means it generates work nobody requested and places on the health system a duty to act on incidental findings it was not looking for. That is a workflow and liability design decision as much as a clinical one, and the vendor materials do not address who owns follow up.

Product function and regulatory scope are described clearly, including which anatomical findings each cleared tool addresses, but performance is not published in the materials reviewed. No sensitivity, specificity, or reader study results were located for the individual products, and no third party head to head benchmarking. As a Nasdaq listed parent the company files detailed SEC disclosures describing the product line, which gives more corporate transparency than most private competitors, but corporate disclosure is not model disclosure.

The regulatory record is substantial, with a reported ten FDA clearances, and independent literature exists on the underlying concept, including a large French study of fully automated opportunistic screening for vertebral fractures and osteoporosis across more than 150,000 routine CT scans. What was not located is peer reviewed outcome evidence specific to these products showing that opportunistic detection changes management or patient outcomes, which is the harder and more relevant question for a population health screening tool. Clearances demonstrate the algorithm detects; they do not demonstrate the program helps.

No specific PHI handling or data governance framework was located. The population health model involves analyzing existing imaging archives at scale for hospitals, HMOs, insurers, and pharmaceutical companies, which raises secondary use questions the vendor materials do not address.

No HIPAA or BAA commitment was located. An Israel headquartered subsidiary of a Nasdaq listed parent selling to US health plans and insurers would need business associate terms established directly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

A deep US clearance portfolio built over years, reported as ten FDA clearances spanning vertebral compression fractures cleared first in May 2020 and again via HealthOST in 2022, coronary artery calcium quantification, pneumothorax, and intracranial hemorrhage. Multiple clearances on the same clinical target, an initial detection clearance followed by a more precise quantitative one, shows iterative regulatory maturation rather than a single legacy clearance. Comfortably an A on breadth and currency of US authorization.

No governance framework, monitoring commitment, or subgroup analysis was located. The gap is notable for a population health product, since opportunistic screening applied across an entire imaging archive will surface findings at different rates across demographic groups, and who gets flagged determines who receives follow up care.

Operates on existing CT archives and delivers findings into clinical workflows, with the parent describing cloud based computing infrastructure supporting its imaging systems. Customers span hospitals, HMOs, integrated delivery networks, insurers, and pharmaceutical companies, which implies varied delivery paths from PACS integration to bulk archive analysis. No named connector list, API documentation, or EHR integration detail was located.

The parent describes cloud based computing infrastructure as part of its cleared system, and the AI products work by mining existing scan archives, which implies scans are processed in vendor infrastructure rather than on premise. Specific tenancy, hosting, and residency terms are not published, which matters given the customer base includes insurers and pharmaceutical companies rather than only treating providers.

No product pricing is published, though the parent is Nasdaq listed and files SEC disclosures describing the business model and product line, which gives more visibility into company finances and strategy than any private imaging AI competitor offers. The parent has publicly described a pay-per-scan model for its imaging hardware, but whether the AI products follow per scan, per site, or population licensing is not disclosed, and the answer materially changes the economics of a screening program run across an entire archive.

Focused by design on opportunistic population health rather than diagnostic breadth: musculoskeletal via vertebral fracture and bone density, cardiovascular via coronary calcium, with hepatic steatosis described as in development, plus acute findings including pneumothorax and brain bleed. The unifying thesis is chronic disease detection from scans already taken, which is a genuinely different market position from triage vendors competing on emergency turnaround. Coverage is CT centric and does not span general radiology.